5 Key Takeaways

• 1

  The focus of ADC development is shifting from potency to tolerability, emphasizing the importance of patient quality of life.

• 2

  Developers must engineer ADCs backward from the patient's daily experience, prioritizing manageable side effects over technical achievements.

• 3

  The industry is encouraged to explore new mechanisms of tolerability and avoid relying solely on limited classes of known toxic payloads.

• 4

  Repurposing 'fallen angel' small molecules as ADC payloads can enhance targeting precision while minimizing systemic toxicity.

• 5

  Innovative linker designs are essential for controlling payload release, improving the therapeutic experience for patients.